<DOC>
	<DOCNO>NCT02442921</DOCNO>
	<brief_summary>Forty patient diabetic nephropathy treat colchicine 2 mg , placebo , 18 month . A follow perform 12 additional month . The primary outcome significant reduction stabilization proteinuria 18 month treatment period .</brief_summary>
	<brief_title>Colchicine Diabetic Nephropathy Trial</brief_title>
	<detailed_description>Diabetic nephropathy lead cause today end stage renal failure western world . Multifactorial intervention patient may slow rate albuminuria renal injury ; however several new drug trial fail far significantly attenuate progression . Several pathway identify development diabetic nephropathy , however , recent year many researcher suspect inflammatory pathway play central role progression diabetic neuropathy . There compel evidence diabetes mellitus auto-inflammatory component Nlrp3 inflammasome interleukin -1 β activation . Colchicine relatively safe anti-inflammatory drug use treat reverse albuminuria familial Mediterranean fever nephropathy , auto-inflammatory disease . Data one study demonstrate colchicine diminish proteinuria inflammation experimental-diabetic animal model . Working hypothesis aim : To assess whether colchicine reduces proteinuria diabetic patient diabetic neuropathy , despite maximal multi-factorial intervention ( angiotensin-converting-enzyme inhibitor , tight glycemic hypertensive control , lifestyle intervention , etc. ) . Methods : Forty patient stable diabetes , diabetic neuropathy proteinuria 0.5-6g/24 hour , despite standard treatment , receive colchicine ( n=20 ) placebo ( n=20 ) 18 month . Urinary protein creatinine clearance assess three month study initiation , baseline every three month thereafter . Blood creatinine , complete blood count , creatine phosphokinase , liver function test , fast Glucose Test , HbA1c , urine protein/creatinine ratio diabetes mellitus treatment monitor follow-up perform every three month . Oral colchicine treatment initiate 1mg per day , increase gradually 2 mg , gastrointestinal musculoskeletal disturbance absent tolerate . The participant call evaluate year end treatment parameter mention . Statistical analysis perform statistician . Expected result : A significant reduction stabilization proteinuria 18 month treatment period , follow one year later . Importance Relevance call This study may define new treatment diabetic nephropathy .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>1 . Patients diabetes mellitus , age &gt; 18 year old , able sign inform consent . 2 . Hemoglobin A1c range 69 % , stable last year ( 0.5± ) 3 . Blood creatinine low 2 mg/dL . 4 . Blood pressure low 140/90 mmHg stable antihypertensive treatment least 3 month . 5 . Treated ACE angiotensin II receptor blocker , unless contraindicate 1 . Malignancy significant heart , lung liver disease . 2 . Any GI disease , inflammatory bowel disease , malnutrition ( BMI 18 ) 3 . Psychiatric disease 4 . Any muscle disease , history rhabdomyolysis , myopathy myositis . 5 . Any disease cause renal injury/proteinuria apart diabetes mellitus 6 . Any inflammatory autoimmune disease 7 . Any infection last month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>